ChiCTR2100045544
Active, not recruiting
Not Applicable
倡导母乳喂养对妇幼健康影响的随机对照试验
瑞士国家科学基金会1 site in 1 country6,000 target enrollmentStarted: June 1, 2021Last updated:
Overview
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- 瑞士国家科学基金会
- Enrollment
- 6,000
- Locations
- 1
- Primary Endpoint
- 母乳喂养率
Overview
Brief Summary
1.本研究的主要目的，是通过临床随机对照研究，评估和比较行为干预如何影响婴儿出生后第一年内的母乳喂养率； 2.本研究的第二个目的是检验母乳喂养对母婴健康的影响； 3.本研究的第三个目的是了解同伴小组的不同特征对母婴健康的影响。
Study Design
- Study Type
- 干预性研究
- Primary Purpose
- 随机平行对照
- Masking
- 未说明
Eligibility Criteria
- Sex
- Female
Inclusion Criteria
- •1.处于 26-32 周的孕期；
- •2.在上海市第一妇婴保健院建卡产检；
- •4.是上海市的居民或者在上海市有全职工作；
Exclusion Criteria
- •1.在之前的三个月孕期经历了胎儿死亡；
- •2.在之前经历过新生儿死亡；
- •3.在本孕期被诊断患有癌症；
- •4.被诊断为乙肝表面抗原阳性；
- •5.有人造乳房植入物；
- •7.在干预对照随机分组前分娩；
- •8.其胎儿疑似或被诊断患有严重疾病或异常。
Arms & Interventions
干预组
母乳喂养应用程序
对照组
无母乳喂养应用程序
Outcomes
Primary Outcomes
母乳喂养率
女性产后心理健康
幼儿身体健康
儿童发展指标
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Once-A-Day Pregabalin For Partial SeizuresCTRI/2011/08/001976Pfizer Limited264
Active, not recruiting
Phase 1
A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-19 patientsSARS-CoV-2 infected patientsMedDRA version: 23.0Level: LLTClassification code 10084270Term: SARS-CoV-2 acute respiratory diseaseSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-002299-11-HUSigmaDrugs Research Ltd.100
Active, not recruiting
Phase 1
A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening over 48 weeks in children (6 to 11 years old) with moderate persistent asthma - Tiotropium in children with moderate persistent asthmaModerate persisten asthmaMedDRA version: 16.1Level: LLTClassification code 10003560Term: Asthma NOSSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2011-001758-26-HUBoehringer Ingelheim RCV GmbH & Co KG615
Active, not recruiting
Phase 1
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs SyndromeEUCTR2005-005372-32-DKGlaxoSmithKline Research & Development Ltd400
Active, not recruiting
Not Applicable
A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole CR 1-24mg administered once daily for 12 weeks in subjects with fibromyalgia.EUCTR2004-001680-22-ITGLAXO SMITHKLINE